Impact BioMedical, Inc. - נכסים נקיים למניה בודדת IBO

Impact BioMedical Inc (IBO) is implementing a patent monetization strategy through licensing agreements with industry behemoths. Growth is driven by the market launch of the 3F repellent and the sale of intellectual property rights. The company is developing antibacterial solutions to combat fungal resistance. The net book value per share reflects the organization's current capital, with the indicator standing at 1.27.

The specifics of Impact BioMedical Inc. (IBO) biotechnological developments are characterized by low cyclicality and long-term licensing demand, which makes the company dependent on venture financing. This metric reflects the residual value of net assets after all liabilities are settled, allowing the investor to assess the business's internal resilience to macro shocks and the risk of write-downs through the dynamics of equity per share.